What additional therapy might a patient with severe atopic dermatitis benefit from alongside topical regimen?

Patients with severe atopic dermatitis often experience significant skin inflammation and discomfort that may not be adequately managed with topical therapies alone. In such cases, the addition of systemic immunomodulators or biologics can provide further therapeutic benefits.

Systemic immunomodulators, such as methotrexate or cyclosporine, help to modify the immune response, reducing inflammation and improving the skin’s condition. On the other hand, biologics like dupilumab specifically target pathways involved in the inflammatory process of atopic dermatitis, leading to significant improvement in symptoms and overall skin health.

The use of these advanced therapies is especially important for patients with moderate to severe atopic dermatitis, where traditional topical treatments may not yield sufficient control of the disease. Therefore, the additional therapy of systemic immunomodulators or biologics is essential in managing the condition effectively, particularly when quality of life is adversely affected.